About

Eabha (pronounced "Ava") is building the next generation of validation and quality tools for prenatal screening. We develop synthetic cell-free DNA references and genomic AI to help labs deliver more accurate, reliable results for expecting families.

What We Do

Non-invasive prenatal testing (NIPT) has transformed how we screen for chromosomal conditions during pregnancy. But as the field grows, so does the need for better validation tools. Current approaches rely on limited clinical samples that are expensive, inconsistent, and hard to standardize across labs.

Eabha takes a different approach. We engineer synthetic cfDNA that mimics the complexity of real maternal plasma samples - giving labs a programmable, reproducible way to validate their screening pipelines. Combined with our genomic AI models, we help prenatal screening providers catch errors before they reach patients.

What You Will Find Here

This blog is where we share our thinking on the science, technology, and future of prenatal diagnostics. Topics include:

• Advances in NIPT and cell-free DNA analysis
• How synthetic biology is reshaping diagnostic validation
• Genomic AI and its applications in prenatal screening
• Perspectives on quality, regulation, and lab operations
• Technical deep dives into cfDNA biology and bioinformatics

Get in Touch

Whether you are a lab director, researcher, or just curious about the future of prenatal screening, we would love to hear from you. Visit eabhaseq.com to learn more about our products and team.